Avadel Pharmaceuticals — Investor Presentation (March 2017)
26 slides from Avadel Pharmaceuticals's investor presentation, Mar 17, 2017
Slide 1: Avadel Pharmaceuticals plc
a ; id Avadel Pharmaceuticals plc wAvadel | “=m Ma Maren 2017
Slide 2: Safe Harbor
Safe Harbor Yr Avadel This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” "believe," "expect,"
Slide 3: Who is Avadel?
Yr Avadel Whois Avadel? — — Coreg CR® using ° Micropump? received FDA - Established in 1990 to FLAMEL approval (GSK partnered provide life cycle solutions product) to large pharma using its polymer-based drug delivery technology === i) 9 ECLAT FLAMEL sk FS Coedatics ‘yAvadel — Acquired Eclat ~ FDAap
Slide 4: Investment Highlights
Investment Highlights u w Avadel ~ Revenue guidance of $170 - $200M up from $150.2M in 2016 — Adjusted diluted EPS of $0.20 - $0.35 up from a loss of ($0.06) in 2016 2017 Outlook ~ Cash flow positive ~ $25M share buyback ~ Phase III trial FT218 — Current market size > $1B ~ Data expected 1H 2018 G *
Slide 5: Recent Highlights
u Recent Highlights w Avadel ¥ Generated total revenues of $150.2 million in 2016 ¥ Completed cross-border merger from France to Ireland ¥ Commenced dosing for REST-ON Phase III trial of Micropump® sodium oxybate (FT218) ¥ Initiated development of 4** unapproved marketed product (UMD), AV001 - NDA f
Slide 6: Pipeline
Pipeline \ Avadel Drug / Technology pproved So im Oxybate / MicroPump® Indication: Narcolepsy Unapproved Marketed Drug (avo) ination Undelosed ( LiquiTime® / MicroPump® Indication: CNS. Indication: Psychiatrie Indication: Pediatric Indication: Pediatric | = LiquiTime® coe oc Hydromorphone / Trigger
Slide 7: Micropump Overview
Micropump® Overview Yr Avadel Microparticulate system that allows the development of modified and/or controlled release of solid, oral dosage formulations of drugs Validated Technology Micropump® Granules: = Druggranulate or layered neutral core = Polymer coating Consists of multiple-dose system con
Slide 8: LiquiTime Overview
LiguiTime® Overview Yr Avadel Potential Advantages + Intended for development of modified/controlled release liquid formulations for patients having issues swallowing tablets/capsules + Not limited to working solely with ionic drugs as with resin- complex based technologies | + Easy-to-swallow, good
Slide 9: Narcolepsy Overview
\yAvadel Narcolepsy Overview — Asleep disorder, involving irregular patterns in Rapid Eye Movement (REM) sleep and significant disruptions of normal sleep/wake cycle ~25% - Estimated “200,000 > Only 25% of people -"12,900 diagnosed patients -Xyrem® generated ‘Americanssuffer from Withnarcolepsy have
Slide 10: FT218: Potential for Improved Treatment
x FT218: Potential for Improved Treatment \ Avadel FT218: Once-nightly formulation of sodium oxybate utilizing Avadel’s proprietary extended-release Micropump® microparticle technology for oral suspension Studied in 40 healthy volunteer £7218 potential to provide: ¥ Comparable AUC as Xyrem® on dose-
Slide 11: REST-ON Phase III Clinical Trial
REST-ON Phase lll Clinical Trial Double-Blind, Randomized, Placebo-Controlled, Study to Assess Safety and Efficacy of Once Nightly Sodium Oxybate (FT218) for the Treatment of Excessive Daytime Sleepiness (EDS) and Cataplexy in Patients with Narcolepsy Maren 2017 1
Slide 12: REST-ON Phase III Trial
REST-ON Phase III Trial Trial Design* + 264 Patients, ages 16 + * 50-60 Clinical sites across US, Canada, Western Europe * Patients must be sodium oxybate naive * Efficacy measured by Maintenance of Wakefulness Test (MWT), Clinical Global Impression (CGI) rating of sleepiness and number of cataplexy
Slide 13: Hospital Products
Hospital Products Maren 2017 Pediatric Products
Slide 14: Hospital Products
Hospital Products Yr Avadel First to gain FDA approval for neostigmine, ephedrine and full-line phenylephrine Akovaz® (ephedrine sulfate injection) * Market volume~ 7.5 million vials / year Bloxiverz® (neostigmine methylsulfate injection) * Market volume ~ 4 million vials / year Vazculep® (phenyleph
Slide 15: Pediatrics
Pediatrics Yr Avadel — AcipHex’ Pa cipHex . . Karte cscinon GEL ACLOR, Sprinkle’ Oflexichamboer ‘oral suspension /4mg/SmL 425mg. 250ma/5mt-375mg3m (rabeprazole sodium) een ee Delayed-Release Capsules * Acquired 3 commercial stage pediatric-focused sa products (February 2016) = = ¢ Flexichamber® laun
Slide 16: Intellectual Property
u Intellectual Property w Avadel rt Micropump® July 2027 July 2023 LiquiTime September 2025 April 2023 Trigger Lock™ April 2027 May 2026 (pending) Medusa™ June 2031 June 2027 (pending) Prout us| Karbinal» ER March 2029 Flexichamber' March 2028 Product specific IP combined with platform IP extends pa
Slide 17: Non GAAP Financial Results
a Non GAAP Financial Results w Avadel == (in. 000s) ‘Twelve Months Ended 12/31/16 12/31/15 Sales $ 150,246 $173,009 Cost of products and services sold 12,742 11,410 Research and development expenses 34,611 25,608 Selling, general and admin expenses 44,179 21,712 Intangible asset amortization Operati
Slide 18: Cash Flow Summary
u Cash Flow Summary \ Avadel — in $000's Twelve Months Ended December 31, 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance $ 144,802 $ 92,834 Operating Cash Flows (excl tax and earnout payments) 68,801 126,414 Tax Payments (27,180) (42,121) Earnout/Royalty Payments (30,837) (27,897)
Slide 19: Investment Highlights
u Vv Investment Highlights \ Avadel - Revenue guidance of $170 - $200M up from $150.2M in 2016 ~ Adjusted diluted EPS of $0.20 - $0.35 up from a loss of ($0.06) in 2016 ~— Cash flow positive ~ $25Mshare buyback 2017 Outlook Phase Ill ~ Phase III trial FT218 - is — Current market size > $1B Trial ~ D
Slide 20: Appendix
Appendix Maren 2017
Slide 21: GAAP to NON-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations \rAvadel ‘Twelve Months Ended December 31, 2026: Adit Maren 2017 n
Slide 22: GAAP to NON-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations \rAvadel ‘Twelve Months Ended December 31, 2015: 2 us05, Total revenue Cost of produc and Total operating expenses Operatingincome (loss) Income (Iss) before income taxes Net Loss Netloss per share -Diluted Weigntes average number of snares cutstonding -Diuted ‘Adjus
Slide 23: Trigger Lock
Trigger Lock™ \yAvadel Two pilot PK studies comparing 3 Trigger Lock hydromorphone (FT227) prototypes to comparator product, Jurnista® at a dose of 32mg * Studied in 30 healthy volunteers + Fasted condition: 16 subjects + Fedcondition: 14 subjects + No safety or tolerability issue observed + Bioequi
Slide 24: Medusa
Medusa™ Yr Avadel Release of the unmodified drug by diffusion, disaggregation of the depot and competition with endogenous proteins over several days r Glut id Depot formation jutamic aci 3 Injection Day 4 orig 7 Natural and safe components disappearing progressively Phase lb — exenatide (FT228) in
Slide 25: Management Team
u Management Team \ Avadel — Michael Anderson Gregory Divis Michael Kanan, Phil Thompson Chief Executive Officer EVP, Chief Commercial Officer SVP, Chief Financial Officer SVP, General Counsel + Appointed CEO in 2012 + Appointed CCO in January + Appointedin 2015 + Appointedin 2013 + Former CEO of Ec
Slide 26: Product & Safety Information
Product & Safety Information — \yAvadel Please click below or visit our websites for full prescribing and safety information for our marketed products Bloxiverz® www.bloxiverz.com Vazculep® www.vazculep.com Akovaz™ www.akovaz.com Maren 2017 Karbinalw ER www.karbinaler.com Aciphex® Sprinkle™ http://w
Avadel Pharmaceuticals — Investor Presentation (March 2017) on 6ix